These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19517472)

  • 1. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.
    Gold HT; Hall MJ; Blinder V; Schackman BR
    Cancer; 2009 Sep; 115(17):3858-67. PubMed ID: 19517472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
    Butzke B; Oduncu FS; Severin F; Pfeufer A; Heinemann V; Giessen-Jung C; Stollenwerk B; Rogowski WH
    Acta Oncol; 2016; 55(3):318-28. PubMed ID: 26098842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.
    Pichereau S; Le Louarn A; Lecomte T; Blasco H; Le Guellec C; Bourgoin H
    J Pharm Pharm Sci; 2010; 13(4):615-25. PubMed ID: 21486535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
    Ma CJ; Huang CW; Yeh YS; Tsai HL; Hu HM; Wu IC; Cheng TL; Wang JY
    Oncol Res; 2017 May; 25(5):673-679. PubMed ID: 27938508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
    Palomaki GE; Bradley LA; Douglas MP; Kolor K; Dotson WD
    Genet Med; 2009 Jan; 11(1):21-34. PubMed ID: 19125129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
    Lévesque E; Bélanger AS; Harvey M; Couture F; Jonker D; Innocenti F; Cecchin E; Toffoli G; Guillemette C
    J Pharmacol Exp Ther; 2013 Apr; 345(1):95-101. PubMed ID: 23386248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
    Okuyama Y; Hazama S; Nozawa H; Kobayashi M; Takahashi K; Fujikawa K; Kato T; Nagata N; Kimura H; Oba K; Sakamoto J; Mishima H
    Jpn J Clin Oncol; 2011 Apr; 41(4):477-82. PubMed ID: 21303789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics and irinotecan therapy.
    Hahn KK; Wolff JJ; Kolesar JM
    Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
    Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.
    Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY
    Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2009 Jan; 11(1):15-20. PubMed ID: 19125128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
    Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY
    Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
    Deeken JF; Slack R; Marshall JL
    Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
    Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J
    Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
    Kweekel DM; Gelderblom H; Van der Straaten T; Antonini NF; Punt CJ; Guchelaar HJ;
    Br J Cancer; 2008 Jul; 99(2):275-82. PubMed ID: 18594531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
    Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
    Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.
    Wei X; Cai J; Sun H; Li N; Xu C; Zhang G; Sui Y; Zhuang J; Zheng B
    Pharmacogenomics; 2019 Mar; 20(4):241-249. PubMed ID: 30628534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
    Miyata Y; Touyama T; Kusumi T; Morita Y; Mizunuma N; Taniguchi F; Manabe M
    Int J Clin Oncol; 2016 Aug; 21(4):696-703. PubMed ID: 26710796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
    Liu D; Li J; Gao J; Li Y; Yang R; Shen L
    BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.